Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Short-term Investments (2016 - 2023)

Ironwood Pharmaceuticals' Short-term Investments history spans 14 years, with the latest figure at $788000.0 for Q3 2023.

  • On a quarterly basis, Short-term Investments fell 36.96% to $788000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $788000.0, a 36.96% decrease, with the full-year FY2022 number at $1.3 million, up 4.0% from a year prior.
  • Short-term Investments hit $788000.0 in Q3 2023 for Ironwood Pharmaceuticals, roughly flat from $788000.0 in the prior quarter.
  • Over the last five years, Short-term Investments for IRWD hit a ceiling of $11.3 million in Q2 2021 and a floor of $788000.0 in Q2 2023.
  • Historically, Short-term Investments has averaged $2.5 million across 5 years, with a median of $1.2 million in 2019.
  • Biggest five-year swings in Short-term Investments: crashed 97.48% in 2019 and later surged 800.96% in 2021.
  • Tracing IRWD's Short-term Investments over 5 years: stood at $1.2 million in 2019, then soared by 36.0% to $1.7 million in 2020, then dropped by 26.47% to $1.2 million in 2021, then grew by 4.0% to $1.3 million in 2022, then plummeted by 39.38% to $788000.0 in 2023.
  • Business Quant data shows Short-term Investments for IRWD at $788000.0 in Q3 2023, $788000.0 in Q2 2023, and $1.2 million in Q1 2023.